Surmodics Inc SRDX.OQ SRDX.O is expected to show a rise in quarterly revenue when it reports results on January 31 (estimated) for the period ending December 31 2024
The Eden Prairie Minnesota-based company is expected to report a 9.2% increase in revenue to $33.367 million from $30.55 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Surmodics Inc is for a loss of 12 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Surmodics Inc is $43.00, above its last closing price of $35.79.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.30 | -0.29 | -0.13 | Beat | 55.8 |
Jun. 30 2024 | -0.33 | -0.33 | -0.27 | Beat | 18.2 |
Mar. 31 2024 | -0.32 | -0.32 | 0.07 | Beat | 121.9 |
Dec. 31 2023 | -0.32 | -0.30 | 0.00 | Beat | 100 |
Sep. 30 2023 | 0.18 | 0.19 | 0.53 | Beat | 186.5 |
Jun. 30 2023 | -0.22 | 0.05 | 0.52 | Beat | 893.7 |
Mar. 31 2023 | -0.49 | -0.51 | -0.40 | Beat | 21.3 |
Dec. 31 2022 | -0.65 | -0.66 | -0.50 | Beat | 23.8 |
This summary was machine generated January 29 at 13:34 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)